Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress
Data from first two dose levels of Nana-val in patients with EBV+ recurrent/metastatic nasopharyngeal carcinoma…
Africa’s First CoC Registry Goes Live for SA’s 20 September Trade Deadline
Santamarina + Steta Strengthens Its Tax Practice with the Addition of Luis Curiel Pina and Francisco Carbajal Dominguez
Berry AI and Culver’s Announce Brand-Wide Vision AI Deployment Across 1,000+ Restaurants
Sensiba Names Monic Ramirez as Managing Partner Amid Firm-Wide Transformation